Wegovy and Mounjaro are both prescription-only medicines used for weight management — but they’re not identical twins in matching outfits.
Wegovy contains semaglutide, while Mounjaro contains tirzepatide.
They work in slightly different ways, have different dosing schedules, and people can respond differently to them.
So why do the doses keep changing? What happens if you’re already losing weight on a low dose? Do you have to keep moving up? And what does the research actually tell us?
Let’s take a look.
Why do you start on such a low dose?
Both medicines are introduced gradually rather than starting at the highest dose.
With Wegovy injections, the usual starting dose is 0.25 mg once weekly, with the dose normally increased gradually according to the licensed dosing schedule.
Mounjaro also begins at a low dose and is increased gradually.
One reason for this gradual approach is tolerability, particularly gastrointestinal side effects such as nausea.
Think of it as giving your body a polite introduction before the medicine moves in and starts rearranging the furniture.
But what if you’re already losing weight on the starting dose?
It can happen.
Some people may notice changes in appetite or weight quite early in treatment.
The important thing to understand is that a starting dose is part of a dosing schedule. Losing weight while taking it doesn’t automatically mean somebody should either remain on that dose indefinitely or increase it sooner.
Those decisions should be discussed with the prescriber.
In other words, your body responding early isn’t a race invitation.
Do you have to keep increasing the dose?
The two medicines have their own licensed dosing schedules, but reaching the highest possible dose as quickly as possible isn’t the objective.
Dose decisions can depend on factors including response to treatment and side effects, and should be made with the healthcare professional responsible for prescribing the medicine.
There is, after all, no medal for reaching the highest dose first.
What do the trials actually show?
This is where it’s useful to look at the evidence rather than the internet rumour mill.
One important direct comparison is the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025.
The 72-week study directly compared tirzepatide with semaglutide in adults with obesity but without type 2 diabetes.
On average, participants receiving tirzepatide experienced greater weight reduction than participants receiving semaglutide.
But — and this is quite an important “but” — clinical trials report averages.
They cannot tell us exactly how one individual will respond to either medicine.
Medical history, suitability, tolerability, side effects and individual response all matter.
So the research gives us useful evidence.
It doesn’t give us a crystal ball.
And then there’s the price
Prices for Wegovy and Mounjaro can vary considerably.
The amount somebody pays may depend on the medicine, dose, pharmacy, delivery charge and whether a particular price is introductory or ongoing.
That makes comparing prices slightly more complicated than simply spotting the lowest number on a page.
A starting price may not represent what someone would pay later in treatment if their prescribed dose changes.
For anyone looking at the financial side of treatment, it can therefore be useful to understand costs across different doses rather than concentrating solely on an introductory price.
Because small monthly differences have an annoying habit of becoming much bigger annual ones.
So is one better than the other?
That’s not really the question this article is trying to answer.
Wegovy and Mounjaro contain different active ingredients and have different dosing schedules.
Clinical research can tell us what happened on average to groups of people taking the medicines.
It cannot determine which treatment is suitable for a particular individual.
That decision needs to take account of medical history, suitability, response and side effects and should be made with an appropriately qualified healthcare professional.
The bottom line
Yes, somebody may notice weight loss while taking a lower dose.
No, getting to the highest dose first isn’t the goal.
And a medicine producing greater average weight loss in a clinical trial doesn’t automatically tell us what will happen to the next person who takes it.
When it comes to Wegovy and Mounjaro, there is plenty to compare — but individual treatment decisions belong between the patient and their healthcare professional.
Health Compare UK provides independent price-comparison information to help people understand differences between UK pharmacy costs. Health Compare UK does not prescribe, dispense or recommend prescription-only medicines.
Sources
- SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, published in the New England Journal of Medicine, 2025.
- Current UK official prescribing information for Wegovy (semaglutide).
- Current UK official prescribing information for Mounjaro (tirzepatide).
Information is provided for general informational purposes and should not replace advice from a qualified healthcare professional.